Drug Trial Radar · NCT04701476
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
May 20, 2021
Primary completion
Mar 31, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Teclison Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jan 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Conditions
- Colorectal Cancer; Lung Cancer
Interventions
TATE and pembrolizumabDrug
All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.
TAS-102 pillDrug
The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.
Regorafenib PillDrug
As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival for the mCRC cohortTime frame: 24 months
- Overall Response Rate (ORR) for the NSCLC cohortTime frame: within 24 months
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Irvine Medical Center
Orange, California · Recruiting
China Medical University Hsinchu Hospital
Hsinchu, Taiwan · Recruiting
Chung Shan Medical University Hospital
Taichung, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.